Physician profile
Navin Kumar
NPI 1790901940
$12,185.49
in general payments reported to CMS, 2019-2025
38 companies · $1,979 in 2025
The $1,979 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,428 · 2020: $1,377 · 2021: $1,742 · 2022: $2,088 · 2023: $1,926 · 2024: $1,645 · 2025: $1,979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,550.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,166.36 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,090.56 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Nestle Healthcare Nutrition INC. | $1,986.11 | 2020-2023 | |
| Janssen Biotech, INC. | $1,007.26 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,003.08 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Allergan, INC. | $398.23 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $247.69 | 2019-2024 | |
| Genzyme Corporation | $215.42 | 2023-2025 | |
| Pfizer INC. | $192.16 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $173.18 | 2022-2023 | Dificid |
| Olympus America INC. | $148.07 | 2024 | Endocapsule Recorder, Visiglide, Hanarostent Esophagus Tts(Ccc) |
| Celgene Corporation | $135.87 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $132.80 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $106.63 | 2024-2025 | Zenpep |
| Romark Laboratories, Lc | $100.91 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $90.92 | 2024-2025 | Omvoh |
| Vivus LLC | $83.62 | 2021-2025 | Pancreaze |
| Cook Medical LLC | $83.39 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $81.26 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $76.74 | 2023-2025 | Ibsrela |
| Braintree Laboratories, INC. | $76.29 | 2020-2025 | Sutab, Suflave |
| Qol Medical, LLC | $70.65 | 2024-2025 | Sucraid, Sucraid |
| Shionogi INC | $64.59 | 2019-2020 | |
| Covidien LP | $64.52 | 2019 | |
| Sandoz INC. | $45.30 | 2023-2024 | Hyrimoz |
| Ucb, INC. | $44.75 | 2019 | |
| Madrigal Pharmaceuticals | $44.01 | 2025 | Rezdiffra |
| Celltrion USA INC. | $40.60 | 2025 | Vegzelma |
| Medtronic, INC. | $39.19 | 2021 | |
| Ferring Pharmaceuticals INC. | $28.01 | 2020 | |
| Gilead Sciences, INC. | $25.49 | 2024 | |
| Fresenius Kabi USA, LLC | $23.30 | 2023 | Idacio |
| Micro-Tech Endoscopy USA, INC. | $20.71 | 2022 | |
| Evoke Pharma, INC. | $17.68 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.04 | 2024 | Cyltezo |
| Capsovision, INC. | $15.91 | 2023 | Capsocam Plus |
| Boston Scientific Corporation | $14.76 | 2020 | |
| Shire North American Group INC | $13.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navin Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.